Warning: selective serotonin reuptake inhibitors in children and adolescents by Control Council, National Adverse Drug Event Monitoring Centre, Medicines
September 2005, Vol. 95, No. 9  SAMJ
SAMJ FORUM
The Medicines Control Council (MCC) has resolved that
manufacturers of selective serotonin reuptake inhibitors (SSRIs)
update the package inserts for their products to include
warning statements alerting health care providers to an
increased risk of worsening of depression and suicidality
(suicidal thinking and behaviour) in patients being treated with
these agents, and to include additional information about the
use of these medicines in children and adolescents.
The risk of suicidality for these medicines was identified in a
combined analysis of short-term (up to 4 months) placebo-
controlled trials of antidepressant agents, including the SSRIs
and others, in children and adolescents with major depressive
disorder (MDD), obsessive-compulsive disorder (OCD) or
other psychiatric disorders. A total of 24 trials involving over 
4 400 patients were included. The analysis showed a greater
risk of suicidality during the first few months of treatment in
those receiving antidepressants. The average risk of such
events on drug was 4%, twice the placebo risk of 2%. No
suicides occurred in these trials.1
On the basis of these data, prescribers should be alerted to
the following points:
• None of the SSRIs are currently approved in South Africa for
any indication in children and adolescents. 
• SSRIs have been associated with an increase in the risk of
suicidal thinking and behaviour (suicidality) in children and
adolescents with MDD and other psychiatric disorders.2
• Products containing citalopram, escitalopram, fluvoxamine,
paroxetine, sertraline and venlafaxine are contraindicated in
children under 18 years of age, as safety and efficacy have
not been established in this age group. The package inserts
for these products are being updated accordingly.
• Discontinuation of SSRIs, especially abrupt discontinuation,
commonly leads to significant withdrawal symptoms.2 When
stopping treatment of an SSRI the dose should be tapered
over an appropriate period of time. The package insert for
the SSRI should be referred to.
The MCC is currently working with the manufacturers of all
approved antidepressant agents to optimise the safe use of
these medicines and implement the product package insert
changes and other safety communications in a timely manner.
Health professionals are encouraged to report any adverse
reactions associated with the use of medicines to the MCC’s
National Adverse Drug Event Monitoring Centre by telephone
(021) 447-1618 or fax (021) 448- 6181.
National Adverse Drug Event Monitoring Centre
Medicines Control Council
Cape Town
1.    FDA Public Health Advisory, 15 October 2004. Suicidality in children and adolescents being
treated with antidepressants. www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm
(last accessed 15 August 2005).
2.    European Medicines Agency/CHMP/128918/2005. Press Release: European Medicines
Agency finalises review of antidepressants in children and adolescents.
http://www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf (last accessed 15 August 2005).
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